Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$87.73 USD

87.73
4,499,207

-1.77 (-1.98%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $87.73 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (155 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights Visa, Novartis, Deere & Company, Airbnb, and Edwards Lifesciences

Visa, Novartis, Deere & Company, Airbnb, and Edwards Lifesciences have been included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Visa, Novartis & Deere

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Novartis AG (NVS), and Deere & Company (DE).

Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of 25.81% and 285.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Edwards Lifesciences (EW) Now

Investors are optimistic about Edwards Lifesciences' (EW) robust segmental performance and growing product uptake.

Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Edwards Lifesciences (EW) closed at $102.25, marking a -1.16% move from the previous day.

Why Edwards Lifesciences (EW) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Edwards Lifesciences (EW) Stock Moves -0.68%: What You Should Know

Edwards Lifesciences (EW) closed at $111.61 in the latest trading session, marking a -0.68% move from the prior day.

Why Is Edwards Lifesciences (EW) Up 7.5% Since Last Earnings Report?

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Edwards Lifesciences (EW) Stock Moves -0.58%: What You Should Know

Edwards Lifesciences (EW) closed the most recent trading day at $105.33, moving -0.58% from the previous trading session.

Here's Why You Should Retain Edwards Lifesciences (EW) Stock

Investors are optimistic about Edwards Lifesciences (EW) on continued strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system.

The Zacks Analyst Blog Highlights: AbbVie, Edwards Lifesciences and Johnson Controls International

AbbVie, Edwards Lifesciences and Johnson Controls International are included in this analyst blog.

Edwards Lifesciences (EW) Q4 Earnings Fall Shy of Estimates

Strong sales growth across all four product groups along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) fourth-quarter revenues.

Mark Vickery headshot

Top Analyst Reports for AbbVie, Edwards Lifesciences & Johnson Controls

Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. (ABBV), Edwards Lifesciences Corporation (EW), and Johnson Controls International plc (JCI).

Edwards Lifesciences (EW) Lags Q4 Earnings and Revenue Estimates

Edwards Lifesciences (EW) delivered earnings and revenue surprises of -7.27% and 1.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Tracey Ryniec headshot

5 Big Cap Earnings All Stars to Watch This Week

Get ready. Tesla and Microsoft are among the tech titans that will report. Can they beat again?

Why Edwards Lifesciences (EW) Might Surprise This Earnings Season

Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Edwards Lifesciences (EW) to Post Q4 Earnings: What's in Store?

Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) fourth-quarter results.

Edwards Lifesciences (EW) to Report Q4 Results: Wall Street Expects Earnings Growth

Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Edwards Lifesciences (EW) Stock Sinks As Market Gains: What You Should Know

Edwards Lifesciences (EW) closed at $118.26 in the latest trading session, marking a -1.83% move from the prior day.

Why Edwards Lifesciences (EW) Could Beat Earnings Estimates Again

Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Edwards Lifesciences (EW) closed at $122.30, marking a -0.75% move from the previous day.

Edwards Lifesciences (EW) at 52-Week High: What's Driving It?

Robust performance across the Critical Care and TAVR businesses is driving the top line for Edwards Lifesciences (EW).

The Zacks Analyst Blog Highlights: Tesla, Adobe, Merck, Edwards Lifesciences and Norfolk Southern Corp

The Zacks Analyst Blog Highlights: Tesla, Adobe, Merck, Edwards Lifesciences and Norfolk Southern Corp

Mark Vickery headshot

Top Stock Reports for Tesla, Adobe & Merck

Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Adobe Inc. (ADBE), and Merck & Co., Inc. (MRK).

Edwards Lifesciences' (EW) SAPIEN 3 With Alterra Gets FDA Nod

Edwards Lifesciences' (EW) SAPIEN 3 system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation.